[1. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PloS One 2016; 11(7): e0158765.10.1371/journal.pone.0158765493490527383068]Search in Google Scholar
[2. Hruska KA, Sugatani T, Agapova O, et al. The chronic kidney disease – mineral and bone disorder (CKD-MBD): Advances in pathophysiology. Bone 2017; 100: 80–86.10.1016/j.bone.2017.01.02328119179550271628119179]Open DOISearch in Google Scholar
[3. Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003; 22: 6267–6276.10.1093/emboj/cdg5991463398629184014633986]Open DOISearch in Google Scholar
[4. Figurek A, Spasovski G. Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder? Int Urol Nephrol 2018; 50(10): 1863–1870.3003067710.1007/s11255-018-1935-530030677]Search in Google Scholar
[5. Cejka D, Marculescu R, Kozakowski N, et al. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 2014; 99: 248–255.10.1210/jc.2013-278624187403]Search in Google Scholar
[6. Sabbagh Y, Graciolli FG, O’Brien S, et al. Repression of osteocyte Wnt/-catenin signaling is an early event in the progression of renal osteodystrophy. J. Bone. Miner. Res. 2012; 27: 1757–177210.1002/jbmr.163022492547]Open DOISearch in Google Scholar
[7. Bielesz BO, Hempfing T, Kieweg H, et al. Sclerostin declines during hemodialysis and appears in Dialysate. Blood Purif 2014; 38: 30–36.10.1159/00036499225228355]Search in Google Scholar
[8. Yamada S, Tsuruya K, Tokumoto M, et al. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis. Nephrology (Carlton) 2015; 20: 639–645.10.1111/nep.1250925974190]Search in Google Scholar
[9. Desjardins L, Liabeuf S, Oliveira R.B, et al. Uremic toxicity and sclerostin in chronic kidney disease patients. J Clin Endocrinol Metab 2014; 99: E1854-61.]Search in Google Scholar
[10. Satoa M, Hanafusab N, Kawaguchia H, et al. A Prospective Cohort Study Showing No Association Between Serum Sclerostin Level and Mortality in Maintenance Hemodialysis Patients. Kidney Blood Press Res 2018; 43: 1023–103310.1159/00049082429940587]Search in Google Scholar
[11. Carvalho Goncalves FL, Elias RM, dos Reis L.M, et al. Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrology 2014; 15: 190.10.1186/1471-2369-15-190426542225465028]Search in Google Scholar
[12. Drechsler C, Evenepoel P, Vervloet MG, et al. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2015; 30: 288–293.10.1093/ndt/gfu30125248363]Search in Google Scholar
[13. Nowak A, Artunc F, Serra AL, et al. Sclerostin quo vadis ? – Is this a useful long-term mortality parameter in prevalent hemodialysis patients? Kidney Blood Press Res 2015; 40: 266–276.]Search in Google Scholar
[14. Sooling ASK, Harslof T, Langdahl B. The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis 2018; 10(5-6): 105–115.10.1177/1759720X18775936600909429942362]Search in Google Scholar
[15. Brandenburg VM, Verhulst A, Babler A, et al. Sclerostin in chronic kidney disease – mineral and bone disorder think before you block it! Nephrol Dial Transplant 2018 May 24. doi: 10.1093/ndt/gfy129.10.1093/ndt/gfy12929846712]Open DOISearch in Google Scholar
[16. Xue-Li Du, Wen-Bo Li, and Bo-Jie Hu. (2018) Application of artificial intelligence in ophthalmology. Int J Ophthalmol 11(9): 1555–1561.]Search in Google Scholar